The primary objectives of the study are to estimate and rank-order the longitudinal standardized mean changes over 6 months and over 12 months, for a set of outcome measures administered to participants with amyotrophic lateral sclerosis (ALS), in order to identify measures that are more sensitive to disease progression than Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). The secondary objectives of this study are: To evaluate the test-retest reproducibility of each outcome measure; To determine correlations between 6 and 12-month changes in all exploratory measures with 18 and 24-month changes in ALSFRS-R and survival; To assess correlations between/among the various measures; To obtain biological samples in order to identify molecular correlates to the clinical measures and to further characterize previously identified and novel molecular biomarkers of disease progression for incorporation into future clinical studies.
Study Type
OBSERVATIONAL
Enrollment
138
University of California San Diego Medical Center
San Diego, California, United States
California Pacific Medical Center
San Francisco, California, United States
University of South Florida
Tampa, Florida, United States
The Emory Clinic
Atlanta, Georgia, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Massachusetts General Hospital, MA
Charlestown, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
UZ Leuven
Leuven, Belgium
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
...and 11 more locations
Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)
EIM is an electrophysiological technique in which current is applied to a muscle of interest and resultant voltage and impedance are measured. These measured parameters reflect the conductivity of underlying tissue and presumably the pathologic state of denervated muscle in an ALS participant
Time frame: Baseline to Month 6 and Baseline to Month 12
Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)
CMAP is a standard electrophysiological measure generated by maximally stimulating a nerve such that all muscle fibers innervated by the respective nerve are depolarized. Reduction of CMAP amplitude reflects loss of motor axons and, therefore, is directly relevant to ALS.
Time frame: Baseline to Month 6 and Baseline to Month 12
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)
Optional, to be administered at each site's Investigator's discretion. MUNE is used to estimate the number of functioning motor units.
Time frame: Baseline to Month 6 and Baseline to Month 12
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)
MUNIX estimates functioning motor units within a muscle. CMAP and surface electromyography potentials (surface interference patterns) are obtained at various levels of voluntary effort, and MUNIX is estimated using power and area of CMAP and surface interference patterns.
Time frame: Baseline to Month 6 and Baseline to Month 12
Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)
HHD tests isometric strength of multiple muscles using standard participant positioning. Approximately 10 muscle groups will be examined (per each side) in both upper and lower extremities.
Time frame: Baseline to Month 6 and Baseline to Month 12
Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)
Vital capacity will be measured by means of an SVC test, administered in the upright position. Upright SVC will be determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society.
Time frame: Baseline to Month 6 and Baseline to Month 12
Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
The ALSFRS-R has been demonstrated to predict survival. The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48 \[Cedarbaum 1999\], with higher scores representing better function.
Time frame: Baseline to Month 6 and Baseline to Month 12
Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM
Time frame: Day 1 and Day 7
Within-participant test-retest reliability between the 2 repeated measurements for CMAP
Time frame: Day 1 and Day 7
Within-participant test-retest reliability between the 2 repeated measurements for MUNE
Time frame: Day 1 and Day 7
Within-participant test-retest reliability between the 2 repeated measurements for MUNIX
Time frame: Day 1 and Day 7
Within-participant test-retest reliability between the 2 repeated measurements for HHD
Time frame: Day 1 and Day 7
Within-participant test-retest reliability between the 2 repeated measurements for SVC
Time frame: Day 1 and Day 7
Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R
Time frame: Day 1 and Day 7
Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival
Time frame: Baseline to Month 24
Comparison between 6-month changes for muscle electrophysiological measures
Time frame: Baseline to Month 12
Comparison between 6-month changes for muscle strength measures
Time frame: Baseline to Month 12
Comparison between 6-month changes for functional measures
Time frame: Baseline to Month 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Comparison of molecular biomarkers with disease progression
Time frame: Baseline to Month 12